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ABSTRACT Monoclonal antibody 2F10 is an "internal-
image" anti-idiotype (anti-id) antibody capable of micking the
group-specific "a" determinant of human hepatitis B surface
antigen (HBsAg). By mRNA sequencing and computer-assisted
molecular modeling of monoclonal antibody 2F10, we identified
a 15-amino acid region of the heavy-chain hypervariable region
that has partial residue homology with sequences of the "a"
determinant epitopes of HsAg. We have established that a
linear 15-mer peptide from a contiguous region on the anti-id
antibody can (i) generate anti-HBsAg-specific antibodies when
injected into mice, (ii) prime murine lymph node cells for in vitro
HBsAg-speciflc T-ceff prolerative responses, and (ii) stimulate
in vitro human CD4+ T cells that were primed in vivo to HBsAg
by natural infection with hepatitis B virus or v itio with a
commercially available lBsAg vaccine. Siflcant y, this pep-
tide could also stimulate CD4+ T cells ofhuman hepatitis B virus
carriers. We conclude that a 15-mer peptide derived frot the
anti-id sequence can duplicate the B- and T-cell stimulatory
activity of the intact anti-id antibody and the antigen that is
mimicked, HBsAg.
Infection with human hepatitis B virus (HBV) results in a
gamut of clinical symptoms ranging from minor flu-like
symptoms to death. The wide spectrum of responses is
believed to be accounted for by the host's immune response
to the virus because HBV is not directly cytopathic for
hepatocytes (1). The specific serologic marker of HBV in-
fection is the envelope protein, hepatitis B surface antigen
(HBsAg), which contains three related proteins designated S,
M (S plus pre-52), and L (M plus pre-Sl). All ofthese proteins
share the 226-amino acid sequence of the S protein (in this
paper, HBsAg will refer to the S protein). HBsAg possesses
a common group-specific a determinant and two sets of
mutually exclusive subtype-specific determinants d/y and
w/r. Because antibodies directed toward the a determinant
confer protection against HBV infection, regardless of sub-
type (2), any vaccine developed to prevent HBV infection
should elicit immunity to the a determinant.
The immune network theory proposed by Jerne (3) predicts
the appearance of several types of anti-idiotype (anti-id)
antibodies during the immune response to a given antigen.
The subset of "internal-image" anti-id antibodies (termed
Ab2f3) has been proposed to be anti-paratopic and to mimic
the molecular features of the original antigen (4, 5). This
working hypothesis is based on the concept that certain
homologous or analogous molecular motifs of the anti-id
sequence can mimic specific immunogenic epitopes of the
infectious organism, thereby inducing a protective immune
response (4, 5). Such anti-id antibodies have been used in
various experimental systems as surrogate vaccines against
specific bacterial, viral, and parasitic organisms (for review,
see refs. 6 and 7).
We produced six monoclonal anti-id antibodies against a
monoclonal antibody (mAb), designated H3F5 (id) (8), which
recognizes the protective a determinant epitope on HBsAg
[residues S-(139-147)]. All the anti-id antibodies inhibited the
binding of HBsAg to the H3F5 id; however, only two of these
anti-ids (2F10 and 4D4) were tentatively classified as internal-
image anti-id antibodies by described criteria (9). The anti-id
2F10 was further studied to determine whether it could mimic
HBsAg and generate specific B- and T-cell responses. Anti-id
2F10 could elicit, in several mouse strains, anti-HBsAg
antibodies and prime T cells in vivo that could subsequently
be stimulated in vitro by HBsAg (43); 2F10 could also
stimulate in vitro CD41 T cells from human donors that had
been primed in vivo to HBsAg as a result of vaccination or
HBV infection (10).
To identify the epitopes responsible for this observed
mimicry, we began an extensive structural analysis of anti-id
2F10. We show that the mimicry of HBsAg by anti-id 2F10
is associated with a 15-amino acid sequence on its heavy-
chain (H chain) hypervariable region. This sequence is par-
tially homologous with a determinant epitopes ofHBsAg, and
a synthetic peptide corresponding to this sequence can du-
plicate the B- and T-cell stimulatory activity of the intact
anti-id and HBsAg.
MATERIALS AND METHODS
In Vivo and in Vitro Stimul. H3F5 is mouse mAb (lgG2b)
that is specific for the protective a determinant epitope
S-(139-147) on HBsAg (8) and is the id that anti-id 2F10
recognizes. 2F10 is a mouse internal-image anti-id mAb of the
IgG1 subclass that mimics the group-specific a determinant of
HBsAg (9). mAbs 2F10 and H3F5 were purified from ascites
fluid by 45% ammonium sulfate precipitation and then pas-
sage over a protein A column. The murine mAb 2C3 (anti-
phthalate, IgGl) was used as an isotype control (S. Ghosh,
Indiana State University). Soluble recombinant HBsAg
(rHBsAg) and rHBsAg-alum, devoid of pre-S proteins, were
provided by W. F. Miller (Merck Sharp & Dohme). 2F10
peptide was synthesized by solid-phase methodology (Mul-
tiple Peptide Systems, San Diego) and was conjugated to
keyhole limpet hemocyanin (KLH) via glutaraldehyde.
Abbreviations: HBsAg, hepatitis B surface antigen; rHBsAg, re-
combinant HBsAg; HBV, human hepatitis B virus; mAb, monoclo-
nal antibody; id, idiotype; H chain, heavy chain; L chain, light chain;
VH and VL, variable regions of H chain and L chain, respectively;
CDR, complementarity-determining region; KLH, keyhole limpet
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Gel Electrophoresis and Immunoblotting. One-dimensional,
discontinuous SDS/12% PAGE analysis (Mini-Protean II,
Bio-Rad) as described by Laemmli (11) was done on mAb
2F10 and control mAb 2C3 under reducing and nonreducing
conditions. After electrophoresis, gels were prepared for
immunoblotting and transferred electrophoretically from
SDS gels to nitrocellulose paper (12). The blot was probed
with 125I-labeled H3F5 (id) (100,000 cpm/ml) for 2 hr,
washed, and exposed to Kodak XAR-5 film with a Cronex
intensification screen for 16-18 hr at -70TC.
Primer Extension and Sequencing of mAb 2F10. Primer
extension and sequencing of mAb 2F10 RNA was done
essentially as described by Geliebter (13) by using the primer
5'-CTCACTGGATGGTGGGAAGATGGATACAGT-3' for
the K chain and the primer 5'-CAGGGGCCAGTGGATA-
GAC-3' for yl H chain. The sequence information was
analyzed by the IBI/Pustell DNA sequence-analysis system
of Pustell and Kafatos (14). For comparing mAb 2F10 light-
chain (L) and H-chain amino acid sequences with the HBsAg
amino acid sequence, we used the GAP algorithm of Needle-
man and Wunsch (15).
Modeling ofmAb 2F10. Computer-assisted modeling of the,
Fv region involved interactive graphics modeling based on
canonical structures (16, 17); the parent structures (REI,
HyHEL-5, McPC603) used for the initial modeling have been
solved by x-ray crystallography, and coordinates were ob-
tained from the Brookhaven Protein Data Bank. Residue
homology comparison, canonical scaffolding-building, en-
ergy minimization, conformational searches (18), and dynam-
ics simulation techniques were all used to construct the
model; use of these procedures has been described (19).
Induction ofAnti-HBsAg Antibodies. BALB/c mice (five per
group) were immunized i.p. on days 0, 7, and 14 with either
rHBsAg, anti-id 2F10, or the 15-mer 2F10 peptide. rHBsAg
was administered as an alum-adsorbed precipitate at a dose of
0.5 ,ug per injection. Anti-id 2F10, carrier-free 15-mer 2F10
peptide, or 15-mer 2F10 peptide coupled to KLH (52% peptide
by weight) was administered at 100 gg per injection in com-
plete Freund's adjuvant, incomplete Freund's adjuvant, and
saline, respectively. Mice were bled retroorbitally before and
after immunization, and the sera were evaluated for anti-
HBsAg-specific antibodies using an ELISA kit (AUSAB-
enzyme immunoassay).
In Vitro Proliferation of Mouse Lymph Node T Cells. Mice
were immunized in the hind foot pads with either rHBsAg,
anti-id 2F10, or the 15-mer 2F10 peptide-KLH. Amount of
antigen and schedule of immunization are as described
above. One week after the third injection, the animals were
sacrificed, and the popliteal lymph nodes were collected and
teased apart, the cells were purified as described elsewhere
(20). The enriched T cells were adjusted to a concentration of
2.5 x 105 cells per well. One hundred microliters of cells was
plated in 96-well flat-bottomed plates along with 5 x 105
irradiated syngeneic spleen cells as a source of antigen-
presenting cells. Stimuli diluted in complete medium were
added to the cells in triplicate cultures. The stimuli are as
follows: rHBsAg (0.5 ug per well), anti-id 2F10 and isotype
control antibody (50 ug per well), 2F10 peptide and control
peptide (0.25 Img per well), Con A (1 ,ug per well), or medium
alone. The cells were then cultured for 120 hr as described
(20). Proliferation, as measured by [3H]thymidine incorpo-
ration, was determined by liquid scintillation spectroscopy.
Results are expressed as stimulation index.
Preparation of Human CD4+ T cells. Peripheral blood
mononuclear cells were prepared as described (20). The
technique of Mage et al. (21) as modified by Wysocki and
Sato (22) was used to further purify the peripheral blood
mononuclear cells into a CD41 subset by using the following
antibodies: anti-Leu2a (mouse mAb that recognizes the CD8
cluster on human T cells; predominantly cytotoxic T/sup-
pressor T cells), anti-21.147 (mouse mAb that recognizes the
CD11b/18 cluster and has reactivity against suppressor T
cells, natural killer cells, monocytes, and granulocytes) and
anti-26.263 (mouse mAb that reacts with the f3 chain of
HLA-DR, -DP, and -DQ). All panning reagents were pro-
vided by Robert Evans (Roswell Park Cancer Institute).
CD4+ T-Cell Proliferation Assay. CD4+ cells were cultured
in 96-well flat-bottom plates along with autologous adherent
cells (source of antigen-presenting cells) at a ratio of 2.5 x 105
CD4+ cells/1.25 x 104 adherent cells per well. All cells were
cultured for 7 days in RPMI 1640 medium supplemented as
above (no fetal calf serum), containing 10% heat-inactivated
human AB+ serum. Stimuli used are described above for
mouse T-cell assays.
RESULTS AND DISCUSSION
Determination of Epitopes on Anti-id 2F10 Responsible for
Mimicking the a Determinant of HBsAg. Immunoglobulins
carry antigenic determinants (ids), and id expression may or
may not depend upon the combination of the H and L chains
of the antibody. Reducing SDS/PAGE, followed by immu-
noblot analysis revealed that expression of the internal-image
epitope on anti-id 2F10 did not depend upon the combination
of H and L chains. The H chain of anti-id 2F10 was strongly
detected with the 125I-labeled id (H3F5), whereas the L chain
was only marginally detectable (Fig. 1A). Our earlier studies
had established that T cells obtained from mice primed in vivo
with the intact anti-id, responded vigorously in vitro to
purified H chain but only minimally to purified L chain of
anti-id 2F10 (43).
To further delineate this anti-id epitope, we sequenced the
H- and L-chain variable regions (VH and VL, respectively) of
mAb 2F10 by using standard mRNA sequencing techniques
(13) and deduced the amino acid sequence. The primary
amino acid sequences predicted for the VH and VL segments
of mAb 2F10 are closely associated with the VH of the J558
family and the K chain of the variable region of MOPC-149.
We then compared amino acid sequences of the anti-id H and
L chains with the known sequence of HBsAg by using the
GAP algorithm (15). We first compared amino acid sequences
of the anti-id antibody with a 13-amino acid sequence on
HBsAg [residues S-(135-146)], a region that represents a
partial analogue of the group-specific a determinant (25). This
alignment showed a 58% similarity and 25% identity between
HBsAg-(135-146) and a region encompassing the third com-
plementarity-determining region (CDR3) and part of the
adjacent framework (FR3) ofthe 2F10 H chain (H:88-99; Fig.
1B). We also searched for alignment between amino acids in
the FR3 and CDR3 regions on the anti-id H chain and the
complete HBsAg sequence (226 residues). We obtained val-
ues of 60% similarity and 30o identity for a sequence of 11
residues (124-134) of HBsAg that were adjacent to the 13
residues used in the previous alignment. This region of
HBsAg is also believed to contain a partial group a determi-
nant epitope of HBsAg (26). Fig. 1B shows the alignment
obtained. No sequence homology was observed between the
V region of the 2F10 L chain and HBsAg.
Genetic variants ofHBV (arising from immunological pres-
sure) have been defined, which correspond to amino acid
substitutions within the protective a determinant region of
HBsAg [S-(139-147)] (27, 28). These reports demonstrated an
identical amino acid substitution of Gly-145 -- Arg in the S
protein of HBV. Recent studies using synthetic peptides
corresponding to residues S-(139-147) of HBsAg, with a
Gly-145 -+ Arg substitution demonstrated a decrease in anti-
genicity and abrogation of in vitro proliferative responses of
both human and mouse T cells primed in vivo to HBsAg (29).
It is important to note that this glycine residue is conserved
within the sequence of the anti-id 2F10 H chain that we have
identified as homologous to the a determinant region of
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FIG. 1. Determination ofepitopes on anti-id 2F10 mAb responsible for mimicking the a determinant ofHBsAg. (A) Composite ofSDS/PAGE
with subsequent immunoblot analysis probed with 1251-labeled H3F5. Lanes: 1 and 2, mAbs 2F10 and 2C3 nonreduced; 3 and 4, mAbs 2F10
and 2C3 reduced. (B) Comparison of the region of deduced amino acid sequence of mAb 2F10 H chain showing homology with the HBsAg
S-region amino acid sequence. - -, Identity; -, similarity. S-region amino acids of HBsAg use the numbering system in Valenzuela et al. (23).
The numbering system of anti-id 2F10 is as in Fig. iD. (C) Computer-simulated model of mAb 2F10 Fv region depicting the H chain CDR3
residues H:% to H:100b (white), other H- and L-chain CDRs (green), and framework regions (blue). (D) The solvent-accessible surface (SAS)
van der Waals area (VDW A) of the CDRs was calculated according to the algorithm ACCESS (24); the SAS area of the H chain CDR3 is shown;
residues H:96Y-H:lOObY are highly exposed.
HBsAg. Some other important residues to consider corre-
spond to positions that distinguish serological subtypes of
HBV from each other and additionally some positions for
which information is available on amino acid replacement and
its effect on immunological reactivity of HBsAg. Lysine
occupies position 141 in the HBsAg sequence, whereas argi-
nine occupies that position in the anti-id sequence. However,
we have previously shown, by deliberate amino acid replace-
ment, that a Lys -3 Arg substitution at this position does not
alter the ability of the peptide to elicit T-cell proliferation of
human cells in vitro (29). On the other hand, at position 142
there is a proline in the HBsAg sequence and a glycine in the
anti-id 2F10 sequence. The presence of a glycine or an
isoleucine at this position has been reported to decrease the
antigenicity of HBsAg (30). At position 143 there is either a
serine or a threonine, depending on the HBV subtype; we
observe a tyrosine at this position in the 2F10 peptide se-
quence. The effect ofsuch a replacement at this position on the
immunogenicity of HBsAg is presently unknown.
Threonine occupies position 126 in almost all HBV sub-
types (except adr, which has an isoleucine); in the anti-id
sequence there is an arginine at this position. However, from
replacement set analysis we know that an arginine replace-
ment does not alter in vitro proliferation of human T cells
obtained from HBsAg-vaccinated donors (20). At position
131 there is a threonine instead ofan asparagine, correspond-
ing to subtypes ayw and adw, respectively; seine at this
position in the anti-id sequence would relate the residue more
closely to threonine than to asparagine. Additionally we
know (20) that deliberate replacement of seine at this posi-
tion is tolerated at the level ofhuman T-cell proliferation. All
subtypes except adw have methionine at position 133, and in
the anti-id we report the presence of leucine. However,
experiments with replacement set analysis have already
established that Met/Lys -) Leu is immunologically toler-
ated (20). Finally, subtype ayw has a Tyr-134, also present in
the anti-id sequence. The presence of tyrosine rather than
phenylalanine at position 134 was also reported by Charnay
et al. (31) and Pasek et al. (32).
To visualize this epitope, computer-assisted molecular mod-
eling oftheH and L chains CDRs ofmAb2FlOwas completed,
using canonical immunoglobulin structure libraries, energy-
minimization techniques, and moleculardynamics simulations
(16, 17, 19, 33). Visual and computational inspection (Fig. 1 C
and D) of the completed mAb 2F10 Fv model revealed that
H-chain amino acids in positions H:96-H:10Ob (Fig. iD) had
considerable surface solvent accessibility (determined by the
algorithm ACCESS (24)]. These dataand the fact that secondary-
structural analysis of this area revealed a #-turn, support the
prediction that this region is probably antigenic (34, 35).
Additionally, such CDR loop motifs have been shown to be
highly antigenic as idiotypic determinants and -have been
identified as the determinants responsible for anti-id molecular
mimicry in another system (36). Based on the sequence
homology searches and examination of the computer-assisted
molecular modeling, we elected to synthesize a 15-mer peptide
(AVYYCTRGYHGSSLY), referred to as 15-mer 2F10 pep-
tide. This peptide was tested to determine whether it could
duplicate the in vitro and in vivo properties displayed by the
intact anti-id 2F10 mAb.
Anti-id 15-me Peptide Can Induce Antodies to the Anti-
gen That the Peptide Mimics. Fig. 2A shows that 15-mer 2F10
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peptide covalently coupled to KLH could successfully elicit
anti-HBsAg antibodies when administered to BALB/c mice,
although the response was less than that seen after injection
of rHBsAg or intact 2F10. Anti-HBsAg antibodies were also
elicited when mice were immunized with the peptide alone
(not conjugated to a protein carrier), providing the initial
evidence that this 15-mer contained not only a B- but also a
T-cell epitope [the antibody response to HBsAg is strictly
T-cell dependent (37)].
Mouse T-Cell Stimulation. To provide further evidence that
the 15-mer 2F10 peptide contained a T-cell stimulatory epi-
tope, BALB/c mice were primed in vivo with the 15-mer 2F10
peptide, and the primed T cells were tested for their ability to
proliferate in vitro to the appropriate stimuli. Fig. 2B shows
that T cells obtained from mice primed in vivo with 15-mer
2F10 peptide can respond in vitro to 15-mer 2F10 peptide and
intact 2F10. More importantly, proliferation also occurs after
in vitro stimulation with HBsAg. This result has significance
in considering the use of this anti-id peptide as an alternative
vaccine. For comparison, mice were also immunized with
rHBsAg or the intact anti-id. Primed T cells from each group
could also be appropriately stimulated (Fig. 2B).
Human T-Cell Stimulation. To demonstrate the efficacy of
our anti-id 15-mer peptide in a more clinically relevant
system, human CD4+ T cells from individuals primed in vivo
by vaccination or from HBV infection were cultured in in
vitro proliferation assays with a panel ofdifferent stimuli. The
results of Fig. 3 clearly establish that anti-id 2F10 15-mer
peptide can stimulate in vitro human CD4+ T cells primed in
vivo by vaccination with the licensed hepatitis B vaccine (i.e.,
A
CD
CMJ
0)
*ID
B
x
4,
c
0
E
cn
1 2 3 4 5 6 7 8
Injections Weeks Post Third Immunization
00
80
60 ..
240 i I +50
2F10 Control rHBsAg 2F10 Control Con A
anti-id antibody peptide peptide
FIG. 2. 2F10 15-mer peptide can elicit anti-HBsAg antibodies in
vivo and can prime T cells for an in vitro HBsAg-specific T-cell
proliferative response in BALB/c mice. (A) Comparison of anti-
HBsAg antibody responses elicited by immunization with rHBsAg-
alum (e), anti-id 2F10 mAb (-), 2F10 15-mer peptide (A), or 2F10
15-mer peptide-KLH (A). Results are expressed as OD 492:660 nm
of the average of five mice per group at a 1:20 dilution. Sera from
mice injected with unconjugated 2F10 15-mer peptide were assayed
at a 1:2 dilution. (B) Results of proliferation assays with purified T
cells from mice primed in vivo with rHBsAg-alum (0), anti-id 2F10
mAb (m), or 2F10 15-mer peptide-KLH (A). Cells were stimulated in
triplicate cultures with the following in vitro stimuli: rHBsAg (0.5 ,ug
per well), anti-id 2F10 mAb and control mAb (50 Itg per well), 2F10
15-mer peptide and control peptide (0.25 ,ug per well), Con A (1 Ag
per well), or medium alone.
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FIG. 3. Anti-id peptide can stimulate human CD4+ T cells in vitro
that were primed in vivo as a result of vaccination with the licensed
hepatitis B vaccine (RecombiVax, HB; e, ®, e, o, 0); natural
infection with the hepatitis B virus (i, o, u), and hepatitis B carriers(A, A). In vitro stimuli are the same as for Fig. 2B, except phyto-
hemagglutinin (PHA) was used instead of Con A. Each symbol
represents one person.
individuals serologically HBsAg-, anti-HBsAg+, anti-
HBcAg-). These findings agree with those of Fig. 2B with T
cells from mice immunized with rHBsAg. Individuals primed
in vivo to HBsAg from infection with HBV are distinguished
serologically as HBsAg-, anti-HBsAg+, anti-HBcAg+ (nat-
urally infected and recovered individuals) or as HBsAg+,
anti-HBsAg-, anti-HBcAg+ (HBV carriers). In a manner
analogous to that reported above for vaccinated individuals,
CD4+ T cells from naturally infected and immune individuals
could also be stimulated in vitro by anti-id 15-mer peptide,
intact anti-id antibody, and rHBsAg. Thus, 2F10 anti-id
15-mer peptide could stimulate CD4+ T cells primed in vivo
either as a result of vaccination or exposure to live virus.
Before synthesis of the 15-mer 2F10 peptide, we had dem-
onstrated that the intact anti-id antibody could stimulate CD4+
T cells from 27 HBV carriers (M.W.P., A.T., S. Lall, P. Ogra,
and Y.T., unpublished data). When the anti-id 2F10 15-mer
peptide became available, we had the opportunity to test its
usefulness in two additional HBV carrier patients (Fig. 3). It
is significant to note that 2F10 lS-mer peptide and intact 2F10,
which both mimic HBsAg, can stimulate CD4+ T cells from
HBV carriers, whereas the native antigen, HBsAg, cannot. It
may be argued that this anti-id antibody is stimulating T cells
nonspecifically by T-cell receptor crosslinking; however, the
stimulation seen with the monovalent Fab fragment of the
anti-id (data not shown) and the anti-id 2F10 15-mer peptide
refutes this possibility. No in vitro responses were elicited with
peripheral blood mononuclear cells from nonimmune individ-
uals (HBsAg-, anti-HBsAg-, anti-HBcAg-), thus establishing
specificity of the assay (data not shown).
CONCLUSIONS
Mimicry of external antigens by internal-image anti-id
epitopes can occur by either analogous or cross-reactive
homologous id mimicry. As in nature, where most mimicry is
analogous, the same is true for anti-id mimicry, where
elementary interactive components (electrostatic, H bond-
ing, van der Waals, etc.) contribute to the formation of a
three-dimensional region on the anti-id antibody responsible
for mimicry of the external antigen. Thus, where anti-id
epitopes mimic carbohydrate or lipid epitopes, mimicry is
obviously established by a functional conformation rather
than identity at the primary-amino acid-sequence level.
Although many investigators have reported the existence
of anti-id antibodies and their relative usefulness as surrogate
antigens, only limited reports testify to anti-id mimicry due to
homologous cross-reactive id mimicry. Ollier et al. (38) have
shown that the diversity region of the H-chain segment of an
Immunology: Pride et al.
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internal-image anti-id mAb presents a Glu-Ala-Tyr (GAT)-
like epitope. In the rabbit al allotype system, two anti-id
mAbs were produced that show al-like internal image.
mRNA sequencing of these anti-id proteins revealed amino
acid homology on the VH (CDR2) with the nominal antigen,
however, in reverse orientation. Synthetic peptides made
from this al-like region could inhibit the binding of al
immunoglobulin to anti-al antibody (39). No in vivo B- or
T-cell responses to either of these anti-id peptides have yet
been reported. Clearly, the best-studied system to date of
cross-reactive homologous epitope mimicry is the work in the
reovirus type 3 system (36, 40, 41). By amino acid sequencing
and computer-modeling procedures, homology between a
portion of the hemagglutinin on the reovirus type 3 and the
variable regions of an anti-id mAb has been shown (36).
Synthetic peptides from these regions of homology on the
anti-id (VH and VL) antibody show quite different biological
effects (41). The VL peptide defines a predominant B-cell
epitope (which induces potent neutralizing antibodies) and an
epitope that is important in delayed-type hypersensitivity
responses to the reovirus type 3 hemagglutinin. However, the
VH peptide defines a major helper T-cell epitope on the anti-id
that is recognized by reovirus type 3-induced helper T cells.
We have not only identified the homology between the
anti-id region and the a determinant of HBsAg but have also
demonstrated that a synthetic peptide representing this area
of homology can mimic native HBsAg by eliciting specific B-
and T-cell responses in vivo and in vitro. One of the limita-
tions of most synthetic peptides is that they fail to produce a
secondary protective immune response due to a lack of an
anamnestic recognition of helper T-cell epitopes. Sharing of
ids between T and B cells of related antigen specificity would
permit use of the same anti-id/anti-id-derived peptide to
activate both T and B cells for an anamnestic recognition of
similar epitopes on the infectious organism. We have dem-
onstrated that the anti-id 2F10 can stimulate antigen-specific
B and T cells and that a 15-amino acid synthetic peptide can
duplicate these responses. This aspect may circumvent the
problem of using nonhuman antibody preparations (mouse
monoclonal anti-id) in human subjects. Additionally, the
responses seen using anti-id/anti-id-derived peptide in stim-
ulating HBV carrier CD4+ T cells are promising and may also
have relevance in individuals who are nonresponders to the
licensed HBV vaccine. The cellular mechanism for unrespon-
siveness to HBsAg at the T-cell level in HBV carriers has not
been determined. Antigen-specific suppressor mechanisms
and genetically determined nonrecognition have been impli-
cated (42). The anti-id and anti-id peptide may overcome
these limitations because they mimic only a limited portion of
the HBsAg sequence, do not carry suppressor epitopes, and
can probably be recognized by a wide range of human major
histocompatibility complex haplotypes. These results
strongly support the usefulness of the 2F10 15-mer peptide,
not only for experimental animal models but also in a
clinically relevant human system.
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